Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. The program, completed in collaboration with Dalton Pharma Services, established a qualified reference standard to support analytical testing, manufacturing consistency, quality control and future regulatory and clinical activities.
The milestone strengthens the company’s chemistry, manufacturing and controls (CMC) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development and chiral purity testing. Onco-Innovations said the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization and quality control systems.
This development is significant because it addresses a critical step in pharmaceutical development: ensuring that the active ingredient can be consistently produced and accurately measured. For patients and investors, this progress reduces technical risk and moves the company closer to clinical trials. ONC010 is being developed under an exclusive worldwide license to patented technology that targets solid tumors, a major area of unmet medical need.
The company’s focus on oncology places it in a competitive but vital sector of biotechnology. Solid tumors account for the majority of cancer cases, and treatments that can selectively target these growths are highly sought after. By advancing its CMC capabilities, Onco-Innovations is positioning itself to meet regulatory requirements for investigational new drug applications and eventual clinical studies.
For more information, the full press release is available at https://ibn.fm/EefIN. Additional updates regarding ONNVF can be found in the company’s newsroom at https://ibn.fm/ONNVF.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Onco-Innovations Completes Reference Standard Program for Lead Cancer Drug Candidate ONC010.